Contrasting Aptorum Group (NASDAQ:APM) & Spyre Therapeutics (NASDAQ:SYRE)

Aptorum Group (NASDAQ:APM) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Valuation and Earnings

This table compares Aptorum Group and Spyre Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430,000.00	11.09	-$2.83 million	N/A	N/A
Spyre Therapeutics	$890,000.00	1,230.19	-$338.79 million	($4.23)	-4.30

Aptorum Group has higher earnings, but lower revenue than Spyre Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Aptorum Group and Spyre Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	0	0	0	0	0.00
Spyre Therapeutics	0	0	8	1	3.11

Spyre Therapeutics has a consensus price target of $50.86, indicating a potential upside of 179.90%. Given Spyre Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Aptorum Group.

Volatility and Risk

Aptorum Group has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.98, meaning that its share price is 198% more volatile than the S&P 500.

Institutional and Insider Ownership

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by company insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Aptorum Group and Spyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Spyre Therapeutics	N/A	-210.01%	-44.40%

Summary

Spyre Therapeutics beats Aptorum Group on 8 of the 12 factors compared between the two stocks.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

About Spyre Therapeutics

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.